Shantelle Kuria/LinkedIn
Nov 27, 2025, 04:58
Shantelle Kuria – von Willebrand Disease: Complex Protein, Difficult Market
Shantelle Kuria, Master of Science in Molecular Medicine at Imperial College London, posted on LinkedIn:
”Ever cut your finger while cooking… and watched it bleed for a moment before it just… stops?
That tiny, almost forgettable moment is driven by a proetin most people have never heard of: von Willebrand factor (VWF).
A few weeks ago, I was exploring VWF biology in an MSc lecture, at the very same time, I was supporting an early-phase clinical trial in VWD in my CRO role.
Two worlds…academic and operational…aligning around the same protein.
And it made me ask:
- What actually drives innovation in bleeding disorders?
- And why is a rare disease like VWD suddenly gaining strategic momentum across industry?
In the full piece, I unpack:
- Science – why VWF’s chaotic multimer structure matters.
- Early-Phase Reality – why VWD trials are some of the hardest to run.
- Market Shift – how recombinant and engineered designs are reshaping a quiet market.
- IP and Strategy – how manufacturing patents + orphan exclusivity shape who can compete.
Full article here.
(Would love to hear your take on it.)”

Stay updated with Hemostasis Today.
-
Nov 29, 2025, 17:37Almahdi Ali Explores Ipsilateral Paradoxical Thromboembolism at 22nd European Angiology Days 2025
-
Nov 29, 2025, 17:23Jack Shuang Hou Shares Major Neurology Updates This Week
-
Nov 29, 2025, 16:52Federica Fogacci on Further Strengthening Collaboration Within the Lp(a)CCELERATE Study
-
Nov 29, 2025, 16:42Dr Abdul Mannan on the Echinocyte: Mastering the Diagnostic Duality of Artifact vs. Pathology
-
Nov 29, 2025, 16:42Vikas Dua: Heme Next 1.0 A Conference with a Difference
-
Nov 29, 2025, 16:41Hind Ali: Sources Of Error in Cell Counts
-
Nov 29, 2025, 16:40Maxime Dely: Even on a Break, You Can Give
-
Nov 29, 2025, 16:39Shrinidhi Nathany: HemeNext Brings Science, Technology, and Leadership Together
-
Nov 29, 2025, 16:38PF4 Antibody Persistence and Long-term Pathogenicity in VITT
